Human epidermal growth factor receptor 2 (EGFR/HER2)‐positive breast cancer accounts for 15%–20% of all breast cancers and has a high invasive potential and poor outcome before the emergence of anti‐HER2 therapy.3, 4. This evidence concerns the gene EGFR and breast cancer.